DBV Technologies (NASDAQ:DBVT) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of DBV Technologies (NASDAQ:DBVT) from a sell rating to a hold rating in a research report released on Saturday.

Other research analysts also recently issued reports about the company. Citizens Jmp lifted their target price on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Friday. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research note on Friday. Finally, Guggenheim reissued a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $40.25.

DBV Technologies Stock Down 5.4%

NASDAQ DBVT opened at $19.87 on Friday. DBV Technologies has a twelve month low of $7.53 and a twelve month high of $26.18. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -4.46 and a beta of -0.97. The business’s fifty day moving average is $20.89 and its 200 day moving average is $18.87.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The company had revenue of $0.90 million for the quarter, compared to analyst estimates of $1.11 million. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%. On average, research analysts anticipate that DBV Technologies will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Artisan Partners Limited Partnership acquired a new position in DBV Technologies during the 3rd quarter valued at about $519,000. DLD Asset Management LP acquired a new position in DBV Technologies during the 3rd quarter valued at about $250,000. New York State Common Retirement Fund acquired a new position in DBV Technologies during the 3rd quarter valued at about $34,000. Persistent Asset Partners Ltd acquired a new position in DBV Technologies during the 4th quarter valued at about $115,000. Finally, Truvestments Capital LLC boosted its stake in DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares during the last quarter. 71.74% of the stock is owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.